Abstract:Background: In 2003, severe acute respiratory syndrome (SARS) resulted in hundreds of infections and deaths globally. We aim to assess immunogenicity and protective efficacy of purified inactivated Vero-cell SARS vaccine in monkeys.Methods: The cultures of SARS coronavirus (SARS-CoV) BJ-01 strain infected Vero cells were inactivated with beta-propiolactone. Sequential procedures, including ultrafiltration, gel filtration and ion exchange chromatography, were performed to obtain purified inactivated SARS vaccine. The purified SARS vaccine was analyzed with electron microscope, HPLC and Western blotting. We immunized three groups of cynomolgus macaques fascicularis with adjuvant-containing purified vaccine, purified vaccine and unpurified vaccine, respectively, and a fourth group served as a control. Antibody titers were measured by plaque reduction neutralization test. The vaccinated monkeys were challenged with SARS-CoV BJ-01 strain to observe protective efficacy. Additionally, three groups of rhesus monkeys were immunized with different doses of the purified inactivated SARS vaccine (0.5, 1 and 2 mu g/time/monkey) on days 0 and 7, and the monkeys were challenged with SARS-CoV GZ-01 strain. We assessed the safety of the SARS vaccine and observed whether the antibody dependent enhancement (ADE) occurred under low levels of neutralizing antibody in rhesus.Findings: The purity of SARS vaccine was 97.6% by HPLC identification and reacted with convalescent sera of SARS patients. The purified SARS vaccine induced high levels of neutralizing antibodies and prevented the replication of SARS-CoV in monkeys. Under low levels of neutralizing antibody, no exacerbation of clinical symptoms was observed when the immunized monkeys were challenged with SARS-CoV. In this preliminary animal trial, no side effects were detected when monkeys were immunized with purified SARS vaccine either at normal or large doses.Interpretation: The purified inactivated SARS vaccine could induce high levels of neutralizing antibody, and protect the monkeys from the challenge of SARS-CoV. The SARS vaccine prepared in the study appeared to be safe in monkeys. (c) 2005 Published by Elsevier Ltd.

IgG-specific Antibody Response in Rabbits after Immunized with Inactivated SARS Coronavirus

Study on the Response of Specific Antibodies Against SARS-CoV in Patients Infected with SARS

Immunogenicity and Protective Efficacy in Monkeys of Purified Inactivated Vero-Cell Sars Vaccine

Comparison of Immunoglobulin G Responses to the Spike and Nucleocapsid Proteins of Severe Acute Respiratory Syndrome (SARS) Coronavirus in Patients with SARS.

Dynamic Changes in IgG and IgM Antibodies As Clinical Indicators During Recovery Stage in Patients with Severe Acute Respiratory Syndrome

Intranasal Immunization with Inactivated SARS-CoV (Sars-Associated Coronavirus) Induced Local and Serum Antibodies in Mice.

Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits

E2 and E rns of classical swine fever virus C-strain play central roles in its adaptation to rabbits

Identification of a Critical Neutralization Determinant of Severe Acute Respiratory Syndrome (Sars)-Associated Coronavirus: Importance for Designing SARS Vaccines.

Analysis of the early stage antibodies in sera of the subjects immunized with rabies vaccine with IFAT and ELISA

Longitudinal Profiles of Immunoglobulin G Antibodies Against Severe Acute Respiratory Syndrome Coronavirus Components and Neutralizing Activities in Recovered Patients

Neutralizing Antibodies in Patients with Severe Acute Respiratory Syndrome-Associated Coronavirus Infection

[A Follow Up Study of Total IgM, IgG, Nucleoprotein and Spike Protein Antibodies Against Severe Acute Respiratory Syndrome (SARS) Coronavirus in Patients with SARS].

Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry.

IgG antibody response against nucleocapsid and spike protein post-SARS-CoV-2 infection

Evaluation of SARS-CoV-2-Specific IgY Antibodies: Production, Reactivity, and Neutralizing Capability against Virus Variants

[Prospective Clinical Study on Serum Immunity in IgG-antibodies Positive Patients Convalescent from Severe Acute Respiratory Syndrome].

Characterization of antibody responses to SARS‐CoV‐2 in convalescent COVID‐19 patients

Development and Evaluation of an Enzyme-Linked Immunosorbent Assay for Detection of Antibodies Against the Spike Protein of Sars-Coronavirus

Inactivated Sars-Cov Vaccine Prepared from Whole Virus Induces A High Level of Neutralizing Antibodies in Balb/C Mice

Receptor-binding Domain of SARS-CoV Spike Protein Induces Long-Term Protective Immunity in an Animal Model